



## **Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference**

February 18, 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 18, 2021-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10<sup>th</sup> Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/news-events/events-presentations>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

### **About Deciphera Pharmaceuticals**

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit [www.deciphera.com](http://www.deciphera.com) and follow us on LinkedIn and Twitter (@Deciphera).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210218005276/en/): <https://www.businesswire.com/news/home/20210218005276/en/>

#### Investor Relations:

Jen Robinson  
Deciphera Pharmaceuticals, Inc.  
[jrobinson@deciphera.com](mailto:jrobinson@deciphera.com)  
781-906-1112

#### Media:

David Rosen  
Argot Partners  
[David.Rosen@argotpartners.com](mailto:David.Rosen@argotpartners.com)  
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.